RxDoctor Payments Data

Marcia Gold, MD

Internal Medicine · Freehold, NJNPI 1710921804

Payments from drug & device makers

$644in general payments, 2019–2025

Across 15 payments — averaging $42.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$247
  • Medtronic$125
  • Johnson & Johnson$119
  • Abbott$65
  • AbbVie$44
  • Novo Nordisk$27
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$644100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca2$247
Medtronic1$125
Johnson & Johnson3$119
Abbott3$65
AbbVie3$44
Novo Nordisk2$27
Lilly USA, LLC1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$644 in reported general payments places this provider in the 60th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$225,261
Medicare patients
389
Services billed
1,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban251$108,654
XareltoRivaroxaban180$59,532
JanuviaSitagliptin Phosphate48$26,566
MounjaroTirzepatide18$18,093
JardianceEmpagliflozin30$13,919
OzempicSemaglutide12$13,304
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,161
Breo ElliptaFluticasone/Vilanterol14$5,731
EntrestoSacubitril/Valsartan11$5,694
MultaqDronedarone Hcl12$5,616
NamzaricMemantine Hcl/Donepezil Hcl18$5,336
Atorvastatin Calcium624$5,235
GemtesaVibegron12$5,146
Potassium Chloride354$4,887
Pantoprazole Sodium515$4,458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$119$59,532180 claims
Lilly USA, LLCMounjaro$18$18,09318 claims
Novo NordiskOzempic$27$13,30412 claims
AbbVieNamzaric, Synthroid$44$7,93144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Freehold

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →